Navigation Links
Thyroid cancer treatment varies by hospital, U-M study finds
Date:8/16/2011

ANN ARBOR, Mich. Where thyroid cancer patients go for care plays a large role in whether they receive radioactive iodine treatment, a new study from the University of Michigan Comprehensive Cancer Center finds.

While the size and severity of the tumor also played a role in treatment, researchers found unexplained hospital factors had a significant impact on radioactive iodine use.

"What hospital you go to makes a difference in use of radioactive iodine. It doesn't just matter what the tumor looks like, but where you go for care," says lead study author Megan Haymart, M.D., assistant professor of internal medicine at the U-M Medical School.

Results of the study appear in the Aug. 17 issue of the Journal of the American Medical Association.

Thyroid cancer is currently one of the 10 most common cancers in the United States and is expected to become even more common in the next decade as more small, early stage cancers are uncovered.

Radioactive iodine following surgery to remove the thyroid is known to be an effective treatment for advanced or high-risk thyroid cancer that is very likely to return. But patients with small, low-risk disease often have an excellent prognosis without radioactive iodine treatment, giving some doctors pause to wonder whether they are submitting patients to unnecessary treatment and risk of side effects.

"For some patients, radioactive iodine is a very important part of treatment, but for others, the risks may outweigh the benefit. We need more studies of this low-risk group of patients to understand what the best treatment course is," Haymart says.

In the current study, researchers looked at data from 189,219 patients diagnosed with thyroid cancer between 1990 and 2008, as reported to the National Cancer Database, a national database that captures about 85 percent of all thyroid cancers diagnosed in the United States.

Researchers found that radioactive iodine treatment is being used more frequently overall 40 percent of patients in 1990, compared to 56 percent of patients in 2008. Size and severity of the tumor did impact a patient's likelihood to have radioactive iodine, accounting for about 21 percent of the variation in care. In addition, factors such as whether the hospital saw a high volume of thyroid cancer patients played a role. But 29 percent of the variation between whether patients received radioactive iodine was attributable to hospital factors that could not be explained.

"Even among people who are high risk and the guidelines are clear that these patients should receive radioactive iodine there is still variation. This suggests doctors are unclear about the indications for radioactive iodine. We need randomized clinical trials that look at radioactive iodine in low-risk patients so that we can set better guidelines for its use," Haymart says.

Radioactive iodine treatment can have long-term side effects, including risk of a second cancer or damage to nearby tissue such as salivary glands. In addition, safety precautions need to be taken when the treatment is delivered, requiring patients to stay away from young children for a week and avoid becoming pregnant for up to a year after treatment.

Thyroid cancer statistics: 44,670 Americans will be diagnosed with thyroid cancer this year and 1,690 will die from the disease, according to the American Cancer Society


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related medicine news :

1. No End In Sight To The Armour Thyroid Shortage?
2. Thyroid Disease: The Hidden Epidemic
3. Thyroid Hormone Analogue for Treating High Cholesterol
4. Thyroid hormone analogue for treating high cholesterol
5. Overactive Thyroid Linked to Stroke in Young Adults
6. Thyroid condition increases stroke risk in young adults
7. Demonstrated in vivo the transfer of maternal thyroid hormones to the fetus
8. Experts Divided on Whether to Treat Thyroid Cancer
9. Thyroid ultrasound takes center stage at Caesars Palace
10. SNM 2010 image of the year: Molecular imaging shows parathyroid disease in greater detail
11. Flame retardant linked to altered thyroid hormone levels during pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Thyroid cancer treatment varies by hospital, U-M study finds
(Date:5/25/2016)... ... May 25, 2016 , ... CloudLIMS, joins an elite ... Life Sciences Tech Solution Providers list of 2016 by CIOReview. , In a deliberate ... Life Sciences Tech Solution Providers 2016 has been concluded with. The positioning is based ...
(Date:5/25/2016)... ... 25, 2016 , ... DKT International, one of the largest ... pleased to release their 2015 global impact data. In 2015, DKT served over ... deaths and 3.8 million unsafe abortions across 21 countries worldwide. , “We ...
(Date:5/25/2016)... ... , ... Casa Velas, an adults-only boutique hotel in Puerto Vallarta, Mexico, introduces ... wellness suites . The two 1,350 sq. ft. suites which debuted in late ... insuite amenities, from a custom soap selection and in-suite exercise kit to a personal ...
(Date:5/25/2016)... ... ... For more than fifty years, we've suffered whiplash as each new scientific study seemed to ... latest nutritional advice – advice that was supposed to keep us healthy and slim. And ... adults are considered to be overweight and more than 1 in 3 adults are considered ...
(Date:5/25/2016)... ... ... Researchers from SUNY State College of Optometry won the Award for Best ... and human attention. The article, VEP and Human Attention: Translation from Laboratory to ... Vision Testing System (Diopsys, Inc., Pine Brook, NJ) to record visual evoked potentials ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... ARANZ Medical  Ltd a specialist ... has been named the Coretex Hi-Tech Emerging Company of the ... Dr Bruce Davey , CEO of ARANZ Medical says, ... good to be recognised for the work we are doing ... in 35 countries around the world from Sub-Saharan Africa through ...
(Date:5/24/2016)... , May 24, 2016 ... the world , s first dual ... fistula intervention   OrbusNeich, a global company ... expanded its portfolio to include products to treat peripheral ... the company,s first entry devices for lower limb and ...
(Date:5/24/2016)... 24, 2016 Dutch surgeons have launched a ... the world and treat patients on a global scale. Medical professionals ... Asia and the US have already signed ... and networking in a totally secure environment. Education  ... zone working together with a surgeon at Harvard to treat a ...
Breaking Medicine Technology: